Dr. Agarwal's Health Care: Investor Presentation for H1 FY27 Earnings Call
Dr. Agarwal's Health Care's H1'FY27 investor presentation reveals revenue growth of 31.4% YoY to ₹1,269 Cr and EBITDA growth of 50.1% YoY to ₹112 Cr. Q2'FY27 saw revenue grow 27.0% YoY to ₹655 Cr and PAT grow 55.8% YoY to ₹57 Cr. The company highlighted its leadership as India's largest eye care chain with expansion plans.
The investor presentation provides a comprehensive overview of the company's financial performance and strategic direction, which is material information for investors and stakeholders.
The announcement details strong year-over-year growth in revenue and profit, alongside significant operational achievements and expansion plans, indicating a positive financial and business outlook.
Dr. Agarwal's Health Care Limited announced its Investor Presentation for the Analyst/Earnings Conference Call for the quarter and half-year ended September 30, 2026. The presentation, scheduled for November 05, 2026, at 06:30 PM IST, covers the Unaudited Financial Results (Standalone and Consolidated) for the period. The company highlighted its strong performance, noting a 31.4% YoY growth in Revenue from Operations to ₹1,269 Crore for H1'FY27, with EBITDA seeing a 50.1% YoY growth to ₹112 Crore. It also reported a 27.0% YoY growth in Revenue from Operations for Q2'FY27 to ₹655 Crore and a 55.8% YoY growth in Profit After Tax to ₹57 Crore for the same quarter. The company emphasized its position as India's largest eye care services chain, with a diversified presence across 172 cities in India and 9 countries. Key operational highlights include serving over 1,844K+ patients and performing 186K+ surgeries in H1'FY27. The presentation also detailed clinical innovations, such as Pinhole Pupilloplasty (PPP), and outlined expansion plans, including adding more surgical facilities. The financial overview showcased robust growth across various segments and a healthy payor mix.
What to do with a filing like this
Dr. Agarwal's Health Care Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Agarwal's Health Care Limited. Read the original for the full detail.